Global Anesthesia Drugs Market Size (2024 - 2029)

The anesthesia drugs market is projected to experience growth over the forecast period, driven by an increase in surgical procedures and the introduction of new anesthesia drugs. The market's expansion is attributed to the resumption of elective surgeries that were postponed during the pandemic, leading to a rise in demand for anesthesia drugs. Additionally, the development and approval of innovative local anesthesia products are contributing to revenue growth for market participants. These factors collectively enhance the market's capacity and potential for growth.

Market Size of Global Anesthesia Drugs Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Anesthesia Drugs Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 7.26 Billion
Market Size (2029) USD 8.57 Billion
CAGR (2024 - 2029) 3.40 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Anesthesia Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Anesthesia Drugs Market Analysis

The Global Anesthesia Drugs Market size is estimated at USD 7.26 billion in 2024, and is expected to reach USD 8.57 billion by 2029, growing at a CAGR of 3.40% during the forecast period (2024-2029).

Due to the emergence of the pandemic situation, demand for anesthesia drugs decreased slightly in 2020, resulting in surgeries being postponed or canceled. According to a study published in the British Journal of Surgery in May 2020, around 28.4 million elective surgeries worldwide were estimated to be canceled or postponed, based on 12 weeks of peak disruption to hospital services due to COVID-19. However, as activities resume, all of the elective surgeries that had been postponed are now being completed, increasing anesthesia drug consumption.

The primary factors propelling the growth of this market are the rising number of surgeries and new anesthesia drug approvals. According to the American Society of Plastic Surgeons, in 2020, 2.3 million cosmetic surgical procedures, 13.2 million cosmetic minimally invasive procedures, and 6.8 million reconstructive procedures were performed in the United States 2020, representing a 3% increase over 2019. This indicates the rising number of surgeries, which ultimately results in the rising demand for anesthesia drugs.

Moreover, according to the article 'Trauma of Major Surgery' published in the National Center for Biotechnology Information (NCBI) in July 2020, globally, a staggering 310 million major surgeries are performed each year. Similarly, according to the article titled 'Incidence and Cumulative Risk of Major Surgery in Older Persons in the United States published in July 2021, in the United States, Nearly nine major surgeries were performed annually for every 100 older persons, and more than 1 in 7 Medicare beneficiaries underwent a major surgery over five years, representing nearly 5 million unique older people.

Furthermore, the development and approvals of novel local anesthesia drugs are proving to be a new revenue-generating resource for market players. For instance, in February 2021, PainPass launched the first Cannabidiol (CBD)/lidocaine product line targeting those with chronic pain and for numbing muscles externally. In December 2021, Hikma Pharmaceuticals PLC (Hikma), has launched Bupivacaine HCl Injection, USP through its United States affiliate, Hikma Pharmaceuticals United States Inc. The company has launched 0.25%, 0.5% and 0.75% in 10mL and 30mL doses. Moreover, in June 2021, PAION AG received United Kingdom Medicines & Healthcare products Regulatory Agency (MHRA) approval for Byfavo (remimazolam besylate) in adults for procedural sedation.

Thus, all aforementioned factors, such as the increasing number of surgical procedures and product launches, boost the market over the forecast period.

Anesthesia Drugs Industry Segmentation

As per the scope of the report, anesthesia is a drug that induces a reversible loss of sensation. Anesthesia is one of the essential components of any surgical procedure. It induces temporary unconsciousness and loss of protective reflexes. General anesthesia drugs suppress the activities of the central nervous system and induce a complete lack of sensation. Local anesthetics restrict the transmission of nerve impulses from the targeted region to the spinal cord. The anesthesia drugs market is segmented by drug type (general anesthesia drugs and local anesthesia drugs), route of administration (inhalation, injection, and other routes of administration), application (general surgery, cosmetic surgery, plastic surgery, dental surgery, and other applications), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers market size and forecasts in value (USD million) for the above segments.

By Drug Type
General Anesthesia Drugs
Propofol
Sevoflurane
Desflurane
Dexmedetomidine
Remifentanil
Midazolam
Other General Anesthesia Drugs
Local Anesthesia Drugs
Bupivacaine
Ropivacaine
Lidocaine
Chloroprocaine
Prilocaine
Benzocaine
Other Local Anesthesia Drugs
By Route of Administration
Inhalation
Injection
Other Routes of Administration
By Application
General Surgery
Plastic Surgery
Cosmetic Surgery
Dental Surgery
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Anesthesia Drugs Market Size Summary

The anesthesia drugs market is poised for steady growth over the forecast period, driven by an increasing number of surgical procedures and the introduction of new anesthesia drugs. The market experienced a temporary decline in demand due to the COVID-19 pandemic, which led to the postponement of elective surgeries. However, as healthcare activities resumed, the demand for anesthesia drugs surged to accommodate the backlog of surgeries. The market is further bolstered by the development and approval of innovative local anesthesia drugs, which present new revenue opportunities for industry players. The rising prevalence of surgeries, including cosmetic and reconstructive procedures, is a significant factor contributing to the market's expansion. Propofol, a widely used general anesthetic, continues to play a crucial role in the market due to its extensive application in various surgical procedures and critical care settings.

North America currently leads the anesthesia drugs market, with the United States being the largest regional market globally. The region's dominance is attributed to the high volume of surgical procedures, an aging population with chronic conditions, and advancements in anesthesia technologies. The market is characterized by intense competition, with major players holding substantial market shares. However, the landscape is evolving as mid-size and smaller companies introduce new products at competitive prices, expanding their market presence. The ongoing development of new anesthesia drugs and strategic partnerships, such as those seen in the United States and Europe, are expected to further drive market growth. The market's competitive nature and the continuous introduction of innovative products underscore the dynamic environment in which anesthesia drugs are marketed and distributed.

Explore More

Global Anesthesia Drugs Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Number of Surgeries

      2. 1.2.2 New Approvals of Anesthesia Drugs

      3. 1.2.3 Reduction in the Cost of Newly Invented Drugs

    3. 1.3 Market Restraints

      1. 1.3.1 Side Effects of General Anesthetics

      2. 1.3.2 Lack of Skilled Anesthetics

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Drug Type

      1. 2.1.1 General Anesthesia Drugs

        1. 2.1.1.1 Propofol

        2. 2.1.1.2 Sevoflurane

        3. 2.1.1.3 Desflurane

        4. 2.1.1.4 Dexmedetomidine

        5. 2.1.1.5 Remifentanil

        6. 2.1.1.6 Midazolam

        7. 2.1.1.7 Other General Anesthesia Drugs

      2. 2.1.2 Local Anesthesia Drugs

        1. 2.1.2.1 Bupivacaine

        2. 2.1.2.2 Ropivacaine

        3. 2.1.2.3 Lidocaine

        4. 2.1.2.4 Chloroprocaine

        5. 2.1.2.5 Prilocaine

        6. 2.1.2.6 Benzocaine

        7. 2.1.2.7 Other Local Anesthesia Drugs

    2. 2.2 By Route of Administration

      1. 2.2.1 Inhalation

      2. 2.2.2 Injection

      3. 2.2.3 Other Routes of Administration

    3. 2.3 By Application

      1. 2.3.1 General Surgery

      2. 2.3.2 Plastic Surgery

      3. 2.3.3 Cosmetic Surgery

      4. 2.3.4 Dental Surgery

      5. 2.3.5 Other Applications

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle-East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle-East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Global Anesthesia Drugs Market Size FAQs

The Global Anesthesia Drugs Market size is expected to reach USD 7.26 billion in 2024 and grow at a CAGR of 3.40% to reach USD 8.57 billion by 2029.

In 2024, the Global Anesthesia Drugs Market size is expected to reach USD 7.26 billion.

Anesthesia Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)